ENDRA Life Sciences Inc. (NASDAQ:NDRA) Short Interest Down 65.2% in March

ENDRA Life Sciences Inc. (NASDAQ:NDRA) was the target of a large decrease in short interest in March. As of March 13th, there was short interest totaling 53,910 shares, a decrease of 65.2% from the February 26th total of 154,773 shares. Currently, 8.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 86,029 shares, the short-interest ratio is currently 0.6 days.

ENDRA Life Sciences Price Performance

Shares of ENDRA Life Sciences stock traded up $0.84 on Thursday, hitting $4.59. 133,334 shares of the company’s stock traded hands, compared to its average volume of 290,167. The firm’s 50-day moving average price is $3.82 and its two-hundred day moving average price is $4.85. The stock has a market capitalization of $3.44 million, a PE ratio of -0.17 and a beta of -0.08. ENDRA Life Sciences has a one year low of $2.90 and a one year high of $11.96.

Hedge Funds Weigh In On ENDRA Life Sciences

A hedge fund recently bought a new stake in ENDRA Life Sciences stock. Altium Capital Management LLC bought a new position in shares of ENDRA Life Sciences Inc. (NASDAQ:NDRA) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 51,900 shares of the company’s stock, valued at approximately $235,000. ENDRA Life Sciences accounts for approximately 0.9% of Altium Capital Management LLC’s holdings, making the stock its 17th biggest holding. Altium Capital Management LLC owned about 6.92% of ENDRA Life Sciences at the end of the most recent reporting period. Institutional investors own 1.19% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of ENDRA Life Sciences in a research report on Wednesday, January 21st. Ascendiant Capital Markets dropped their target price on ENDRA Life Sciences from $38.00 to $30.00 and set a “buy” rating for the company in a research report on Monday, December 8th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $30.00.

ENDRA Life Sciences Company Profile

ENDRA Life Sciences, Inc (NASDAQ: NDRA) is a medical technology company headquartered in Ann Arbor, Michigan, that focuses on the development and commercialization of Thermoacoustic Enhanced Ultrasound (TAEUS™) imaging. The company’s proprietary TAEUS platform combines conventional ultrasound with thermoacoustic signals to provide non-invasive, real-time temperature monitoring of soft tissue. This technology is designed to improve the safety, efficacy and outcomes of thermal ablation procedures and other heat-based therapies.

ENDRA’s core product line centers on a compact, easy-to-integrate device that augments existing ultrasound systems.